Advertisement

Gliomatosis cerebri: a consensus summary report from the Second International Gliomatosis cerebri Group Meeting, June 22–23, 2017, Bethesda, USA

  • Andres Morales La Madrid
  • Surabhi Ranjan
  • Katherine E. Warren
Meeting Proceedings

Abstract

Gliomatosis cerebri (GC) is an aggressive glioma characterized by an invasive growth pattern and a dismal prognosis. The low incidence and non-specific symptoms at presentation pose unique challenges for early diagnosis and disease-specific research. There is no standard of care for the treatment of patients with a GC phenotype. Understanding the biology of this entity is a critical step in determining effective treatments. Toward this end, the Second International GC Group convened at National Institutes of Health, Bethesda on June 22nd–23rd 2017. This paper summarizes the main conclusions and recommendations for research priorities to fight this fatal condition.

Keywords

Gliomatosis cerebri Meeting Consensus Second International Gliomatosis cerebri Meeting 2017 

Notes

Acknowledgements

List of scientific participants of the Second International Gliomatosis cerebri Group Meeting, June 22–23, 2017, Bethesda, USA: Kenneth Aldape, University Health Network, Canada; Marta Alonso, University Hospital of Navarra, Spain; Terri Armstrong, National Cancer Institute, USA; Timothy Bentley, Purdue University College of Veterinary Medicine, USA; Veronica Biassoni, Fondazione IRCCS Instituto Nazionale dei Tumori, Italy; Anne-Florence Blandin, University of Strasbourg, France; Alberto Broniscer, St. Jude Children’s Research Hospital, USA; David Castel, Gustave Roussy/CNRS, France; Kenneth Cohen, Johns Hopkins Hospital, USA; Benjamin Deneen, Baylor College of Medicine, USA; Ira Dunkel, Memorial Sloan Kettering Cancer Center, USA; Natacha Entz-Werle, CHU Strasbourg, France; Gerrit H. Gielen, University Hospital Bonn, Germany; Mark Gilbert, National Cancer Institute, USA; Stewart Goldman, Northwestern University, USA; Jeffrey Greenfield, Weill Cornell Medicine, USA; Cynthia Hawkins, The Hospital for Sick Children, Canada; Chris Jones, The Institute of Cancer Research, UK; Yasmin Khakoo, Memorial Sloan Kettering Cancer Center, USA; Mark Kieran, Dana Farber Cancer Institute, USA; Amy LeBlanc, National Cancer Institute, USA; Rishi Lulla, Northwestern University, USA; Peter Manley, Dana Farber Cancer Institute, USA; Dragan Maric, National Cancer Institute, USA; Michelle Monje, Stanford University, USA; Andres Morales La Madrid, Hospital Sant Joan de Deu, Spain; Giovanni Morana, Istituto Giannina Gaslini, Italy; Edjah Nduom, National Cancer Institute, USA; Hideho Okada, University of California San Francisco, USA; Roger Packer, Children’s National Health System, USA; Surabhi Ranjan, National Cancer Institute, USA; David Reardon, Dana-Farber Cancer Institute, USA; Karlyne Reilly, National Cancer Institute, USA; Elisabetta Schiavello, Fondazione IRCCS Instituto Nazionale dei Tumori, Italy; Jack Shern, National Cancer Institute, USA; Katherine Warren, National Cancer Institute, USA; Patrick Wen, Dana-Farber Cancer Institute, USA; Jing Wu, National Cancer Institute, USA. We gratefully acknowledge the support provided by the following GC advocacy and research collaboratives: Anne un rayon de soleil, AYJ Fund, Children’s Brain Tumor Foundation, Elizabeth’s Hope, Fey y Misericordia, Franck un rayon de soleil, Izas la Princesa Guisante, Joshua Bembo Project, Kelly and Kyle Fisher, Mathys un rayon de soleil, Robert and Heather Jucha and Rudy A Menon Foundation. We thank the National Institutes of Health for co-sponsoring this meeting. This research was supported by the Intramural Research Program of the National Institutes of Health.

Compliance with ethical standards

Conflict of interest

The authors disclose that there is no conflict of interest.

References

  1. 1.
    Rudà R, Bertero L, Sanson M (2014) Gliomatosis cerebri: a review. Curr Treat Opt Neurol 16(2):1–9CrossRefGoogle Scholar
  2. 2.
    Taillibert S, Chodkiewicz C, Laigle-Donadey F, Napolitano M, Cartalat-Carel S, Sanson M (2006) Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol 76(2):201–205CrossRefPubMedGoogle Scholar
  3. 3.
    Mawrin C, Kirches E, Schneider-Stock R, Boltze C, Vorwerk CK, von Deimling A, Stoltenburg-Didinger G, Bornemann A, Romeike B, Sellhaus B (2005) Alterations of cell cycle regulators in Gliomatosis cerebri. J Neuro-oncol 72(2):115–122CrossRefGoogle Scholar
  4. 4.
    D’Urso OF, D’Urso PI, Marsigliante S, Storelli C, Luzi G, Gianfreda CD, Montinaro A, Distante A, Ciappetta P (2009) Correlative analysis of gene expression profile and prognosis in patients with Gliomatosis cerebri. Cancer 115(16):3749–3757CrossRefPubMedGoogle Scholar
  5. 5.
    Herrlinger U, Jones DT, Glas M et al (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 131(2):309–319CrossRefPubMedGoogle Scholar
  6. 6.
    Glas M, Bahr O, Felsberg J et al (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in Gliomatosis cerebri. Ann Neurol 70(3):445–453CrossRefPubMedGoogle Scholar
  7. 7.
    Sanson M, Cartalat-Carel S, Taillibert S et al (2004) Initial chemotherapy in Gliomatosis cerebri. Neurology 63(2):270–275CrossRefPubMedGoogle Scholar
  8. 8.
    Soffietti R, Rudà R, Laguzzi E et al (2007) Treatment of Gliomatosis cerebri with temozolomide: a retrospective study of the AINO (Italian Association for Neuro-Oncology). In: ASCO Annual Meeting Proceedings 2007: 2033Google Scholar
  9. 9.
    Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumours. Brain Pathol 3(3):255–268CrossRefPubMedGoogle Scholar
  10. 10.
    Broniscer A, Chamdine O, Hwang S et al (2016) Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. Acta Neuropathol 131(2):299–307CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMedGoogle Scholar
  12. 12.
    Ranjan S, Warren KE (2017) Gliomatosis cerebri: current understanding and controversies. Front Oncol 7:165CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Greenfield JP, Castaneda Heredia A, George E, Kieran MW, Morales La Madrid A (2016) Gliomatosis cerebri: a consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26–27, 2015, Paris, France. Pediatr Blood Cancer 63(12):2072–2077CrossRefPubMedGoogle Scholar
  14. 14.
    Carroll KT, Hirshman B, Ali MA et al (2017) Management and survival patterns of patients with Gliomatosis cerebri: a SEER-based analysis. World Neurosurg 103:186–193CrossRefPubMedGoogle Scholar
  15. 15.
    Chen S, Tanaka S, Giannini C et al (2013) Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neuro-oncol 112(2):267–275CrossRefGoogle Scholar
  16. 16.
    Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T (2010) Prognostic factors for patients with Gliomatosis cerebri: retrospective analysis of 17 consecutive cases. Neurosurg Rev 34(2):197–208CrossRefPubMedGoogle Scholar
  17. 17.
    George E, Settler A, Connors S, Greenfield JP (2016) Pediatric Gliomatosis cerebri: a review of 15 years. J Child Neurol 31(3):378–387CrossRefPubMedGoogle Scholar
  18. 18.
    Hipp SJ, Goldman S, Kaushal A et al (2016) A Phase I trial of lenalidomide and radiotherapy in children with newly diagnosed diffuse intrinsic pontine gliomas and high-grade gliomas. Paper presented at International Symposium on Pediatric Neuro-Oncology; June, 2016; Liverpool, UKGoogle Scholar
  19. 19.
    Kalbasi A, June CH, Haas N, Vapiwala N (2013) Radiation and immunotherapy: a synergistic combination. J Clin Invest 123(7):2756–2763CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Patel KR, Lawson DH, Kudchadkar RR et al (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 17(10):1312–1321CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© This is a U.S. government work and its text is not subject to copyright protection in the United States; however, its text may be subject to foreign copyright protection 2018

Authors and Affiliations

  • Andres Morales La Madrid
    • 1
  • Surabhi Ranjan
    • 2
  • Katherine E. Warren
    • 3
    • 4
  1. 1.Pediatric Neuro-Oncology Unit, Department of Pediatric Hematology and OncologyHospital Sant Joan de DeuBarcelonaSpain
  2. 2.Neuro-Oncology Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  3. 3.Pediatric-Oncology Branch, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  4. 4.Neuro-Oncology Section, Pediatric-Oncology Branch, Center for Cancer ResearchNational Cancer InstituteBethesdaUSA

Personalised recommendations